Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 2.01M
Average 1.31M
ALMS Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Alumis Inc. Common StockNASDAQ: ALMS
Other Current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Other current liabilities rises 304.3% from a year ago
Other current liabilities stood at $51.94M at the end of Q2 FY2026, up 304.3% from a year earlier and up 7.0% from the prior quarter. Over 3 fiscal years it compounded at +151.8% a year.
Context
- Other current liabilities amounted to 9.3% of total assets at the end of Q2 FY2026, up 7.2 pp from a year earlier.
- Other current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +304.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 57.08M USD
- Year-over-year change
- +635.1%
- 3-year CAGR
- +151.8%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 57.08M | +635.1% |
| FY2024 | 2024-12-31 | 7.77M | +39.0% |
| FY2023 | 2023-12-31 | 5.59M | +56.2% |
| FY2022 | 2022-12-31 | 3.58M | — |
Other Current Liabilities vs competitors
How ALMS compares with its peers on the latest reported figures
- Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +304.3% is the 4th highest of 9, against a peer median of +39.6%.
- Other current liabilities amounts to 9.3% of total assets for ALMS, versus a peer median of 3.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | Jun 2026 | $51.94M USD | +304.3% | +151.8% | 9.3% |
| Mar 2026 | $48.5M USD | +42.8% | +51.7% | 9.6% | |
| Mar 2026 | $26.53M USD | +408.5% | +27.3% | 8.0% | |
| Mar 2026 | $10.92M USD | +412.4% | +57.5% | 10.9% | |
| Mar 2026 | €10.13M EUR | +36.3% | — | 20.7% | |
| Mar 2026 | $6.06M USD | -39.9% | -8.8% | 3.0% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $2.38M USD | +3154.8% | — | 2.2% |
| Mar 2026 | $1.32M USD | -69.0% | +3.8% | 2.0% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €0 EUR | — | — | 0.0% |
| Dec 2025 | -$3K USD | -125.0% | — | 0.0% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ALMS) | — | +39.6% | +27.3% | 3.0% | |
Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.